Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Data ReadoutdeucrictibantPositive

AI Analysis

Summary

Pharvaris published results from a qualitative study validating patient-reported outcome measures for AAE-C1INH, which informed the design and endpoints of the ongoing Phase 3 CREAATE trial investigating deucrictibant.

Clinical Trial Data

Phase

Phase 3

NCT ID

NCT07266805

Outcome Details

Qualitative study assessing disease burden and validating patient-reported outcome measures for AAE-C1INH published in Frontiers in Immunology

Importance:5/10

Sentiment:

0.30

angioedemahereditary angioedemabradykinin B2 receptor antagonistpatient-reported outcomesclinical trial designoral therapy

Related Companies

$PHVS

Read the original article

Published by GlobeNewswire Clinical Studies on August 6, 2026 10:50 AM

Read Original